As the Penn Medicine Co-Investment Program Director at the University of Pennsylvania, Carter leads Penn Medicine's investments in the cell therapy, gene therapy, mRNA, lipid nanoparticle, and connected health sectors. Carter was previously a Managing Director with Cross Atlantic Capital Partners, a venture capital firm with 4 funds and over $500 million under management, after having founded 2 software companies. Carter holds an MBA from Columbia University and a BA in Philosophy, Politics and Economics from the University of Pennsylvania.